journal article·2025-06-04

Circularization of Aptamer Nanomedicine Improves Nuclease Resistance, Targeted Recognition, and Transdermal Effect for Topical Psoriasis Therapy

Zhe Liu, Yao Xu, Yuyan Qian, Yu Fan, Zhen Fan, Jianzhong Du, Yong Hu

Nano Letters· Volume 25· Issue 22
Publisher page

Abstract

Inhibiting excessive hyperproliferation and inflammatory responses of keratinocytes are two primary tasks against psoriasis, which, however, have not been well integrated by the current available nanomedicines. Herein, we develop a nucleic acid nanomedicine through coassembly of circular aptamers and gold nanoclusters via electrostatic interactions for psoriasis therapy. After topical application, this nanomedicine bearing vascular endothelial growth factor (VEGF) and tumor necrosis factor alpha (TNF-α) aptamers crosses the stratum corneum and enters the deep layers of psoriatic site, from which it specifically inhibits VEGF-mediated keratinocyte proliferation and TNF-α-mediated inflammatory responses simultaneously. More importantly, the circular aptamers further promote the nuclease resistance, targeted recognition, and transdermal effect of the nanomedicine, as compared to their linear counterparts. These improved synergistic actions effectively prevent and cure psoriasis of mice induced by imiquimod. It is anticipated that this study provides a general strategy for targeted regulation of intricate pathological microenvironments beyond psoriasis.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Psoriasis: Treatment and Pathogenesis · Immunotherapy and Immune Responses · Advanced Drug Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Polymeric Materials, School of Materials Science and Engineering

Tongji University

Department of Gynaecology and Obstetrics, Shanghai Key Laboratory of Anesthesiology and Brain Functional Modulation, Clinical Research Center for Anesthesiology and Perioperative Medicine, Translational Research Institute of Brain and Brain-Like Intelligence, Shanghai Fourth People’s Hospital, School of Medicine

Key Laboratory of Advanced Civil Engineering Materials of Ministry of Education, School of Materials Science and Engineering

School of Materials Science and Engineering

East China University of Science and Technology

Funding

National Key Research and Development Program of China · Shanghai Municipal Education Commission · National Science Fund for Distinguished Young Scholars · Fundamental Research Funds for the Central Universities · National Natural Science Foundation of China · Excellent Young Scientists Fund · Interdisciplinary Project in ?Medicine + X? of Tongji University

References (53)

Show source-provided references
1. 10.1016/S0140-6736(07)61128-310.1016/S0140-6736(07)61128-3 ↗
2. 10.1016/S0140-6736(07)61129-510.1016/S0140-6736(07)61129-5 ↗
3. 10.1016/j.autrev.2014.01.00810.1016/j.autrev.2014.01.008 ↗
4. 10.3390/ijms2205271910.3390/ijms22052719 ↗
5. 10.3390/ijms24221609510.3390/ijms242216095 ↗
6. 10.1016/j.cytogfr.2014.10.00910.1016/j.cytogfr.2014.10.009 ↗
7. 10.1038/nri262210.1038/nri2622 ↗
8. 10.1111/j.1462-5822.2012.01802.x10.1111/j.1462-5822.2012.01802.x ↗
9. 10.1111/exd.1415110.1111/exd.14151 ↗
10. 10.1016/S0190-9622(03)00803-X10.1016/S0190-9622(03)00803-X ↗
11. 10.1111/j.1468-3083.2012.04522.x10.1111/j.1468-3083.2012.04522.x ↗
12. 10.1111/j.1365-2133.1992.tb08035.x10.1111/j.1365-2133.1992.tb08035.x ↗
13. 10.1056/NEJMoa06688610.1056/NEJMoa066886 ↗
14. 10.1111/j.1396-0296.2004.04045.x10.1111/j.1396-0296.2004.04045.x ↗
15. 10.1007/s13555-017-0208-z10.1007/s13555-017-0208-z ↗
16. 10.1016/S0190-9622(03)01143-510.1016/S0190-9622(03)01143-5 ↗
17. 10.3390/jcm1315448410.3390/jcm13154484 ↗
18. 10.1111/ijd.1279010.1111/ijd.12790 ↗
19. 10.1016/j.jaad.2005.01.01010.1016/j.jaad.2005.01.010 ↗
20. 10.1067/mjd.2001.11704610.1067/mjd.2001.117046 ↗
21. 10.1111/j.1346-8138.1999.tb02083.x10.1111/j.1346-8138.1999.tb02083.x ↗
22. 10.3390/ijms24171331310.3390/ijms241713313 ↗
23. 10.1038/nrd300310.1038/nrd3003 ↗
24. 10.1016/j.colsurfb.2016.01.02110.1016/j.colsurfb.2016.01.021 ↗
25. 10.1016/j.jconrel.2023.10.03510.1016/j.jconrel.2023.10.035 ↗
26. 10.1208/s12249-021-02116-510.1208/s12249-021-02116-5 ↗
27. 10.1126/sciadv.abl458910.1126/sciadv.abl4589 ↗
28. 10.1016/j.jpba.2013.03.01410.1016/j.jpba.2013.03.014 ↗
29. 10.1021/acsami.0c1572710.1021/acsami.0c15727 ↗
30. 10.1016/j.pharmthera.2022.10817310.1016/j.pharmthera.2022.108173 ↗
31. 10.1073/pnas.050906910210.1073/pnas.0509069102 ↗
32. 10.1089/nat.2015.057310.1089/nat.2015.0573 ↗
33. 10.1002/med.2173710.1002/med.21737 ↗
34. 10.1038/382607a010.1038/382607a0 ↗
35. 10.1016/j.jid.2019.06.14610.1016/j.jid.2019.06.146 ↗
36. 10.1073/pnas.111842510910.1073/pnas.1118425109 ↗
37. 10.1021/jacs.6b0755410.1021/jacs.6b07554 ↗
38. 10.1021/ja209351u10.1021/ja209351u ↗
39. 10.1021/acsnano.1c0526510.1021/acsnano.1c05265 ↗
40. 10.1002/agt2.12010.1002/agt2.120 ↗
41. 10.1016/j.jconrel.2017.10.03410.1016/j.jconrel.2017.10.034 ↗
42. 10.1021/jacs.0c1204410.1021/jacs.0c12044 ↗
43. 10.1002/anie.20210160910.1002/anie.202101609 ↗
44. 10.1002/anie.20200356310.1002/anie.202003563 ↗
45. 10.1016/j.vascn.2021.10705410.1016/j.vascn.2021.107054 ↗
46. 10.1007/s00403000019510.1007/s004030000195 ↗
47. 10.1038/s41416-020-01184-x10.1038/s41416-020-01184-x ↗
48. 10.1002/adma.20197019010.1002/adma.201970190 ↗
49. 10.1002/anie.20200847110.1002/anie.202008471 ↗
50. 10.1038/s41467-019-13381-110.1038/s41467-019-13381-1 ↗
51. 10.1016/j.chempr.2022.04.00310.1016/j.chempr.2022.04.003 ↗
52. 10.1021/acsnano.4c0726510.1021/acsnano.4c07265 ↗
53. 10.1002/adfm.20242301210.1002/adfm.202423012 ↗